Companies › SNTI
Senti Biosciences Inc (SNTI)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001854270 · EDGAR filings · Updated 2026-07-21
Senti Biosciences Inc (SNTI) has reported institutional ownership of 18.1%, with 15 institutional managers holding positions valued at $4.57M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-21 — ARS filed
- 2026-07-21 — PREM14A filed
- 2026-07-16 — SCHEDULE 13D/A filed
- 2026-07-16 — S-3/A filed
- 2026-07-15 — DEFA14A filed
- 2026-07-15 — Current report (8-K) filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, Senti Biosciences Inc has 15 institutional holders and institutional ownership of 18.1%.
Insider activity
Insiders reported 4 transactions (0 buys, 0 sells) across 2 reporting insiders, with a net reported value of $0.
Data flags from SEC filings
Related companies
NASUS PHARMA LTD (NSRX) · XBiotech Inc (XBIT) · HYPERION DEFI INC (HYPD) · VolitionRx Limited (VNRX) · RAFAEL HLDGS INC COM CL B (RFL) · YD BIO LTD (YDES)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.